dc.contributor.author | Korfi, K | en_US |
dc.contributor.author | Mandal, A | en_US |
dc.contributor.author | Furney, SJ | en_US |
dc.contributor.author | Wiseman, D | en_US |
dc.contributor.author | Somervaille, TCP | en_US |
dc.contributor.author | Marais, R | en_US |
dc.date.accessioned | 2017-01-31T15:16:07Z | |
dc.date.available | 2015-02-17 | en_US |
dc.date.issued | 2015-06 | en_US |
dc.date.submitted | 2017-01-30T10:57:59.138Z | |
dc.identifier.issn | 0923-7534 | en_US |
dc.identifier.uri | http://qmro.qmul.ac.uk/xmlui/handle/123456789/19090 | |
dc.description.sponsorship | Kay Kendall Leukaemia Fund (KKL631) and Cancer Research UK (C15759/A12328) | en_US |
dc.format.extent | 1180 - 1187 | en_US |
dc.language.iso | en | en_US |
dc.relation.ispartof | ANNALS OF ONCOLOGY | en_US |
dc.rights | Published by Oxford University Press on behalf of the European Society for Medical Oncology. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. | |
dc.subject | CML | en_US |
dc.subject | BCR | en_US |
dc.subject | ABL1 mutations | en_US |
dc.subject | whole-genome sequencing | en_US |
dc.subject | personalised medicine | en_US |
dc.subject | mechanisms of resistance | en_US |
dc.title | A personalised medicine approach for ponatinib-resistant chronic myeloid leukaemia | en_US |
dc.type | Article | |
dc.rights.holder | © The Author 2015. | |
dc.identifier.doi | 10.1093/annonc/mdv110 | en_US |
pubs.author-url | http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000357997500021&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=612ae0d773dcbdba3046f6df545e9f6a | en_US |
pubs.issue | 6 | en_US |
pubs.notes | No embargo | en_US |
pubs.publication-status | Published | en_US |
pubs.volume | 26 | en_US |